DM is kind of past tense (unless you are dealing with multicrystal averaging) -- I'd use parrot or shelxe instead (both pretty fast and automated). NCS operators as input do not seem to be in fashion these days, so you might have to put up with heavy atoms or partial MR models...
I would not necessarily expect NCS related bits of the density to be fully identical. JED. From: CCP4 bulletin board [mailto:CCP4BB@JISCMAIL.AC.UK] On Behalf Of Tommi Kajander Sent: 20 December 2011 16:19 To: CCP4BB@JISCMAIL.AC.UK Subject: [ccp4bb] density mod., NSC and software.. Dear all, Stupid question: if i do density modification (flattening and extension say from 6 to 4Å) w/o averaging on a symmetrical, say dimer, would you expect the thing stays symmetric nevertheless? (in particular if there is a strong peak in the NCS??) (seems to me it doenst necessarily...) favorite programs for NCS averiging?? DM obviously, and solomon doesnt do it. Others that do it (with out a PDB or atoms to derive it from, but rather operators) Thanks, Tommi Tommi Kajander, Ph.D., Docent Structural Biology and Biophysics Institute of Biotechnology University of Helsinki Viikinkaari 1 (P.O. Box 65) 00014 Helsinki Finland p. +358-9-19158903 tommi.kajan...@helsinki.fi -------------------------------------------------------------------------- AstraZeneca UK Limited is a company incorporated in England and Wales with registered number: 03674842 and a registered office at 2 Kingdom Street, London, W2 6BD. Confidentiality Notice: This message is private and may contain confidential, proprietary and legally privileged information. If you have received this message in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorised use or disclosure of the contents of this message is not permitted and may be unlawful. Disclaimer: Email messages may be subject to delays, interception, non-delivery and unauthorised alterations. Therefore, information expressed in this message is not given or endorsed by AstraZeneca UK Limited unless otherwise notified by an authorised representative independent of this message. No contractual relationship is created by this message by any person unless specifically indicated by agreement in writing other than email. Monitoring: AstraZeneca UK Limited may monitor email traffic data and content for the purposes of the prevention and detection of crime, ensuring the security of our computer systems and checking Compliance with our Code of Conduct and Policies.
